Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Submitted by admin on May 4, 2020 - 10:37am
Source: 
Fierce Biotech
News Tags: 
Alnylam
Vir Biotechnology
COVID-19
RNAi
clinical trials
Headline: 
Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral
snippet: 

Alnylam and Vir Biotechnology have identified an anti-SARS-CoV-2 development candidate, putting them on track to start testing the inhaled RNAi treatment for COVID-19 in humans around the end of the year.

Do Not Allow Advertisers to Use My Personal information